188Re decays by emitting high-energy beta particles (Emax: 2.1 MeV, Eav: 784 keV), which can be used to kill targeted tumor cells. The short half-life (t1/2 = 16.9 h) of 188Re allows it to be used in targeted radionuclide therapy when linked to peptides or antibodies. 188Re decays with a 155 keV (15%) gamma emission suitable for imaging and dosimetry. Combining these properties make 188Re an ideal theranostic agent in clinical nuclear medicine. Furthermore, 188Re is readily available from a 188W/188Re generator which enables the use of nca 188Re in hospitals and remote locations .
|Title of host publication||European Journal of Nuclear Medicine and Molecular Imaging|
|Number of pages||478|
|State||Published - 30 Oct 2020|
|Name||European Journal of Nuclear Medicine and Molecular Imaging |